Navigation Links
Varied Applications of Adult Stem Cells to Treat Host of Disorders in Human

The University of Pennsylvania School of Medicine has isolated a new source of adult stem cells, which have the potential to differentiate into several cell types.// If the cells show no allergic reactions in human and animal studies and are grown in increased magnitude, then it is possible to meet the needs of an individual to treat a host of disorders that includes peripheral nerve disease, Parkinson's disease, and spinal cord injury.

"We are very excited about this new source of adult stem cells that has the potential for a variety of applications," says senior author Xiaowei (George) Xu, MD, PhD, Assistant Professor of Pathology. "A number of reports have pointed to the fact that adult stem cells may be more flexible in what they become than previously thought, so we decided to look in the hair follicle bulge, a niche for these cells." Xu and colleagues report their findings in the latest issue of the American Journal of Pathology.

Hair follicles are well known to be a source for adult stem cells. Using human embryonic stem cell culture conditions, the researchers isolated and grew a new type of multipotent adult stem cell from scalp tissue obtained from the National Institute of Health's Cooperative Human Tissue Network.

The mutipotent stem cells grow as masses the investigators call hair spheres. After growing the "raw" cells from the hair spheres in different types of growth factors, the investigators were able to differentiate the stem cells into multiple lineages, including nerve cells, smooth muscle cells, and melanocytes (skin pigment cells).

The differentiated cells acquired lineage-specific markers and demonstrated appropriate functions in tissue culture, according to each cell type. For example, after 14 days, 20% to 40% of the cells in the melanocyte media took on a weblike shape typical of melanocytes. The new cells also expressed biomarkers typical of pigment cells and when placed in an artificial hum
'"/>




Page: 1 2

Related medicine news :

1. Adult and Children Have Varied Drug Metabolism
2. New Therapy for Lipid Disorder Demonstrates Varied Results
3. Baby Talk Better Than Adult Speech
4. A question on study of Adult Stem Cell
5. Adult COPD or asthma could be effectively treated with Xopenex
6. Adult stem cells in treatment for Multiple sclerosis (MS)
7. The Key To Prevention Of Heart Disease In Adults
8. The Harmful Effects Of Stress in Young Adults
9. Abuse in Childhood Could Result In Heart Disease in Adulthood
10. Adult bone health is dependent on lifestyle we live
11. Adult Stem Cells From Fat Tissues For Healing
Post Your Comments:
Breaking Medicine Technology:Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3Disrupting a destructive duo 3A U of T Mississauga researchers inhibit cancer proteins 9634 1Disrupting a destructive duo 3A U of T Mississauga researchers inhibit cancer proteins 9634 2Ochsner and Rouses Markets Partner for Choose Healthy Initiative 54965 1Ochsner and Rouses Markets Partner for Choose Healthy Initiative 54965 2Ochsner and Rouses Markets Partner for Choose Healthy Initiative 54965 3Nostrils Compete to Relay Key Fragrance 54963 1Nostrils Compete to Relay Key Fragrance 54963 2